Abbvie Inc. Common Stock (ABBV) 57.40 $ABBV
Global Hypercholesterolemia Market 2014-2018 with AbbVie, Astrazeneca, Merck & Co. & Pfizer Dominating
M2 - Mon Jul 07, 4:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h3hp9b/global) has announced the addition of the "Global Hypercholesterolemia Market 2014-2018" report to their offering. The Global Hypercholesterolemia market will grow at a CAGR of 3.81% to 2018 This report covers the present scenario and the growth prospects of the Global Hypercholesterolemia market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various hypercholesterolemia management drugs that are available in the market which includes statins and other serum lipid lowering drugs. The report also presents the vendor landscape and a corresponding detailed analysis of the top five vendors in the Global Hypercholesterolemia market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market. The Hypercholesterolemia market is associated with fierce competition among the market vendors for innovator drugs and generic manufacturers. The existing competition is expected to rise in the forecast period owing to the launch of generic versions for drugs that are set to lose their patent protection in the near-term. For instance, the 2013 fourth quarter sales for Crestor declined in Canada and Australia owing to the loss of exclusivity in these territories. Further, the drug is expected to face an additional decrease in sales as the US patent for the drug candidate is set to expire in 2016, while in the EU and Japan the patent will expire in 2017. In November 2011, Lipitor lost its exclusivity in the US market. Following the entry of its generic versions in May 2012, the US sales of Lipitor decreased by 81 percent in 2012 as compared to the 2011 US sales. According to the report, one of the main drivers in the market is the increasing risk of cardiovascular diseases. Hypercholesterolemia is one of the underlying causes for CVDs. WHO reported that in men aged 40 years, a 10 percent decrease in serum cholesterol levels is associated with a 50 percent reduction in heart disease within 5 years. Hence, risk management for CVDs also involves the reduction of hypercholesterolemia. Key Vendors - AbbVie Inc. - Astrazeneca PLC - Merck & Co., Inc. - Pfizer Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Clinical Pipeline Portfolio - Market Segmentation by Type of Disease - Market Segmentation by MOA - Global Statins Market - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape For more information visit http://www.researchandmarkets.com/research/h3hp9b/global
1 State's Plan to Fight the AIDS Epidemic
Todd Campbell, The Motley Fool - Motley Fool - Sun Jul 06, 12:30PM CDT
The State of New York recently announced its bold plan to fight back against AIDS in a press release titled " Governor Cuomo Announces Plan to End the AIDS Epidemic in New York State ." The goal is simple: make HIV so uncommon that the number of...
IBD 50: Salix, Gilead Among Top Expected EPS Gainers
at Investor's Business Daily - Sat Jul 05, 7:02AM CDT
The Fourth of July is time for backyard grilling and relaxing, but earnings season is right around the corner. So now's the time to look at IBD 50 stocks that are expected to post the strongest earnings gains. The IBD 50 lists companies based on...
Would You Support U.S. Companies Making This "Un-American" Move?
Sean Williams, The Motley Fool - Motley Fool - Fri Jul 04, 7:29AM CDT
Following the deepest recession the U.S. economy has witnessed in seven decades, the bull market that has followed has been equally monumental with the broad-based S&P 500 up practically 200% since its March 2009 low. Beyond just seeing the...
Form 8 (OPD) AbbVie Inc
PR Newswire Europe - Thu Jul 03, 4:47PM CDT
DUBLIN, July 3, 2014 /PRNewswire/ --
Merck, Gilead Lead Race To Eradicate Hepatitis C
at Investor's Business Daily - Thu Jul 03, 4:08PM CDT
Even if you're not a biotech or pharma investor, you've probably caught an earful of news lately about the virus called hepatitis C. From last December's record-breaking launch of Gilead Sciences' (GILD) wonder drug Sovaldi to the controversies about...
Biotech Stocks to Watch Today: AbbVie, Bind Therapeutics, MannKind, and Shire
George Budwell, The Motley Fool - Motley Fool - Thu Jul 03, 7:42AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for AbbVie , Bind Therapeutics , MannKind Corp. and Shire . AbbVie still pursuing Shire Despite three rejections so far, AbbVie is reportedly still...
Should Dividend Investors Eject Abbott Laboratories Stock?
David Williamson, The Motley Fool - Motley Fool - Wed Jul 02, 5:12PM CDT
Dividend aristocrat Abbott Labs has has a long history of rewarding income investors, but after its transformation, is it still one of the sector's top dividend stocks? In this video, Motley Fool health-care analyst David Williamson will be...
Biotech Stock Roundup: Vertex Jumps on Phase III Data, MannKind Scores FDA Approval - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 02, 9:41AM CDT
Highlights last week include positive phase III data on Vertex's cystic fibrosis combination, FDA approval of MannKind's Afrezza and Auxilium's merger deal with QLT Inc.
Global Nicotine Addiction Pipeline Review, H1 2014 - 13 Drug Profiles from 8 Companies
M2 - Tue Jul 01, 9:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gw2rpx/nicotine) has announced the addition of the "Nicotine Addiction - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Nicotine Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nicotine Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - FORUM Pharmaceuticals Inc. - Omeros Corporation - Selecta Biosciences, Inc. - Heptares Therapeutics Ltd. - Embera NeuroTherapeutics, Inc. - Astraea Therapeutics, LLC - Istituto Italiano di Tecnologia - AbbVie Inc. Drug Profiles - encenicline hydrochloride - OMS-405 - (oxazepam metyrapone) - SEL-068 - OMS-527 - AT-1001 - Small Molecule Targeting Orexin 1 - Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - SLV-330 - Vaccine for Nicotine Addiction - Vaccine for Nicotine Addiction - Liposomal Nicotine Vaccine - Small Molecules to Inhibit FAAH for CNS Disorders For more information visit http://www.researchandmarkets.com/research/gw2rpx/nicotine
Why Investors are Wrong about Gilead
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Mon Jun 30, 8:23PM CDT
Big biotech Gilead (Nasdaq: GILD) has gone on a tremendous 200% two year run as its groundbreaking hepatitis-C cure Sovaldi is breaking all expectations with $2.3 billion in just its first quarter of availability. This has led to nothing but...
Gilead Seeks Japanese Approval for Sovaldi - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 4:11PM CDT
Gilead is looking to get Sovaldi approved in Japan.
AbbVie's Oncology Candidate Progresses - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 3:45PM CDT
AbbVie Inc. (ABBV) announced that it has initiated a phase III study on its oncology candidate, veliparib.
Merger Monday: The AbbVie/Shire Saga Continues
Alex Dumortier, CFA, The Motley Fool - Motley Fool - Mon Jun 30, 9:19AM CDT
As we begin an abbreviated trading week due to the Independence Day holiday, U.S stocks are little changed on Monday morning, with the benchmark S&P 500 and the narrower Dow Jones Industrial Average up 0.14% and 0.08%, respectively, at 10:15...
European Stocks Are Mixed; Steady Inflation in Eurozone
at The Street - Mon Jun 30, 5:25AM CDT
European markets are mixed Monday after a relatively strong performance in Asia overnight.
Scheduled Conference Calls, License Agreements, Dividends, Preliminary Proxy statements and Initiation of Clinical Studies - Analyst Notes on Merck, Johnson & Johnson, AbbVie, Valeant and GSK
PR Newswire - Mon Jun 30, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co., Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), AbbVie Inc (NYSE: ABBV), Valeant Pharmaceuticals Intl Inc (NYSE: VRX) and GlaxoSmithKline plc (ADR) (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4237-100free.
Tax-Fleeing Takeover Mania Surges Forward
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat Jun 28, 12:17PM CDT
Health-care companies are increasingly looking to flee the U.S. for lower corporate tax rates and to access cash trapped overseas. While all deals will pale in comparison with Pfizer 's failed pursuit of AstraZeneca , that would-be deal has...
Shire Snubs AbbVie Offer Again, Favorable Ruling for Vyvanse - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 1:25PM CDT
Shire (SHPG) recently announced that it continues to maintain its stance against AbbVie (ABBV)'s acquisition offer.
3 Stocks Boosting The Health Care Sector Higher
at The Street - Thu Jun 26, 12:02PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
Closer Look at Gilead's Slowing Hep C Prescriptions
at The Street - Thu Jun 26, 9:23AM CDT
Is a slowdown in Sovaldi prescriptions the beginning of the highly anticipated "re-warehousing" of patients, or is some other factor at play?
Global Hypercholesterolemia Market 2014-2018 with AbbVie, Astrazeneca, Merck & Co. & Pfizer Dominating
M2 - Mon Jul 07, 4:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h3hp9b/global) has announced the addition of the "Global Hypercholesterolemia Market 2014-2018" report to their offering. The Global Hypercholesterolemia market will grow at a CAGR of 3.81% to 2018 This report covers the present scenario and the growth prospects of the Global Hypercholesterolemia market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various hypercholesterolemia management drugs that are available in the market which includes statins and other serum lipid lowering drugs. The report also presents the vendor landscape and a corresponding detailed analysis of the top five vendors in the Global Hypercholesterolemia market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market. The Hypercholesterolemia market is associated with fierce competition among the market vendors for innovator drugs and generic manufacturers. The existing competition is expected to rise in the forecast period owing to the launch of generic versions for drugs that are set to lose their patent protection in the near-term. For instance, the 2013 fourth quarter sales for Crestor declined in Canada and Australia owing to the loss of exclusivity in these territories. Further, the drug is expected to face an additional decrease in sales as the US patent for the drug candidate is set to expire in 2016, while in the EU and Japan the patent will expire in 2017. In November 2011, Lipitor lost its exclusivity in the US market. Following the entry of its generic versions in May 2012, the US sales of Lipitor decreased by 81 percent in 2012 as compared to the 2011 US sales. According to the report, one of the main drivers in the market is the increasing risk of cardiovascular diseases. Hypercholesterolemia is one of the underlying causes for CVDs. WHO reported that in men aged 40 years, a 10 percent decrease in serum cholesterol levels is associated with a 50 percent reduction in heart disease within 5 years. Hence, risk management for CVDs also involves the reduction of hypercholesterolemia. Key Vendors - AbbVie Inc. - Astrazeneca PLC - Merck & Co., Inc. - Pfizer Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Clinical Pipeline Portfolio - Market Segmentation by Type of Disease - Market Segmentation by MOA - Global Statins Market - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape For more information visit http://www.researchandmarkets.com/research/h3hp9b/global
1 State's Plan to Fight the AIDS Epidemic
Todd Campbell, The Motley Fool - Motley Fool - Sun Jul 06, 12:30PM CDT
The State of New York recently announced its bold plan to fight back against AIDS in a press release titled " Governor Cuomo Announces Plan to End the AIDS Epidemic in New York State ." The goal is simple: make HIV so uncommon that the number of...
IBD 50: Salix, Gilead Among Top Expected EPS Gainers
at Investor's Business Daily - Sat Jul 05, 7:02AM CDT
The Fourth of July is time for backyard grilling and relaxing, but earnings season is right around the corner. So now's the time to look at IBD 50 stocks that are expected to post the strongest earnings gains. The IBD 50 lists companies based on...
Would You Support U.S. Companies Making This "Un-American" Move?
Sean Williams, The Motley Fool - Motley Fool - Fri Jul 04, 7:29AM CDT
Following the deepest recession the U.S. economy has witnessed in seven decades, the bull market that has followed has been equally monumental with the broad-based S&P 500 up practically 200% since its March 2009 low. Beyond just seeing the...
Form 8 (OPD) AbbVie Inc
PR Newswire Europe - Thu Jul 03, 4:47PM CDT
DUBLIN, July 3, 2014 /PRNewswire/ --
Merck, Gilead Lead Race To Eradicate Hepatitis C
at Investor's Business Daily - Thu Jul 03, 4:08PM CDT
Even if you're not a biotech or pharma investor, you've probably caught an earful of news lately about the virus called hepatitis C. From last December's record-breaking launch of Gilead Sciences' (GILD) wonder drug Sovaldi to the controversies about...
Biotech Stocks to Watch Today: AbbVie, Bind Therapeutics, MannKind, and Shire
George Budwell, The Motley Fool - Motley Fool - Thu Jul 03, 7:42AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for AbbVie , Bind Therapeutics , MannKind Corp. and Shire . AbbVie still pursuing Shire Despite three rejections so far, AbbVie is reportedly still...
Should Dividend Investors Eject Abbott Laboratories Stock?
David Williamson, The Motley Fool - Motley Fool - Wed Jul 02, 5:12PM CDT
Dividend aristocrat Abbott Labs has has a long history of rewarding income investors, but after its transformation, is it still one of the sector's top dividend stocks? In this video, Motley Fool health-care analyst David Williamson will be...
Biotech Stock Roundup: Vertex Jumps on Phase III Data, MannKind Scores FDA Approval - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 02, 9:41AM CDT
Highlights last week include positive phase III data on Vertex's cystic fibrosis combination, FDA approval of MannKind's Afrezza and Auxilium's merger deal with QLT Inc.
Global Nicotine Addiction Pipeline Review, H1 2014 - 13 Drug Profiles from 8 Companies
M2 - Tue Jul 01, 9:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gw2rpx/nicotine) has announced the addition of the "Nicotine Addiction - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Nicotine Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nicotine Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - FORUM Pharmaceuticals Inc. - Omeros Corporation - Selecta Biosciences, Inc. - Heptares Therapeutics Ltd. - Embera NeuroTherapeutics, Inc. - Astraea Therapeutics, LLC - Istituto Italiano di Tecnologia - AbbVie Inc. Drug Profiles - encenicline hydrochloride - OMS-405 - (oxazepam metyrapone) - SEL-068 - OMS-527 - AT-1001 - Small Molecule Targeting Orexin 1 - Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - SLV-330 - Vaccine for Nicotine Addiction - Vaccine for Nicotine Addiction - Liposomal Nicotine Vaccine - Small Molecules to Inhibit FAAH for CNS Disorders For more information visit http://www.researchandmarkets.com/research/gw2rpx/nicotine
Why Investors are Wrong about Gilead
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Mon Jun 30, 8:23PM CDT
Big biotech Gilead (Nasdaq: GILD) has gone on a tremendous 200% two year run as its groundbreaking hepatitis-C cure Sovaldi is breaking all expectations with $2.3 billion in just its first quarter of availability. This has led to nothing but...
Gilead Seeks Japanese Approval for Sovaldi - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 4:11PM CDT
Gilead is looking to get Sovaldi approved in Japan.
AbbVie's Oncology Candidate Progresses - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 3:45PM CDT
AbbVie Inc. (ABBV) announced that it has initiated a phase III study on its oncology candidate, veliparib.
Merger Monday: The AbbVie/Shire Saga Continues
Alex Dumortier, CFA, The Motley Fool - Motley Fool - Mon Jun 30, 9:19AM CDT
As we begin an abbreviated trading week due to the Independence Day holiday, U.S stocks are little changed on Monday morning, with the benchmark S&P 500 and the narrower Dow Jones Industrial Average up 0.14% and 0.08%, respectively, at 10:15...
European Stocks Are Mixed; Steady Inflation in Eurozone
at The Street - Mon Jun 30, 5:25AM CDT
European markets are mixed Monday after a relatively strong performance in Asia overnight.
Scheduled Conference Calls, License Agreements, Dividends, Preliminary Proxy statements and Initiation of Clinical Studies - Analyst Notes on Merck, Johnson & Johnson, AbbVie, Valeant and GSK
PR Newswire - Mon Jun 30, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co., Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), AbbVie Inc (NYSE: ABBV), Valeant Pharmaceuticals Intl Inc (NYSE: VRX) and GlaxoSmithKline plc (ADR) (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4237-100free.
Tax-Fleeing Takeover Mania Surges Forward
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat Jun 28, 12:17PM CDT
Health-care companies are increasingly looking to flee the U.S. for lower corporate tax rates and to access cash trapped overseas. While all deals will pale in comparison with Pfizer 's failed pursuit of AstraZeneca , that would-be deal has...
Shire Snubs AbbVie Offer Again, Favorable Ruling for Vyvanse - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 1:25PM CDT
Shire (SHPG) recently announced that it continues to maintain its stance against AbbVie (ABBV)'s acquisition offer.
3 Stocks Boosting The Health Care Sector Higher
at The Street - Thu Jun 26, 12:02PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
Closer Look at Gilead's Slowing Hep C Prescriptions
at The Street - Thu Jun 26, 9:23AM CDT
Is a slowdown in Sovaldi prescriptions the beginning of the highly anticipated "re-warehousing" of patients, or is some other factor at play?
